A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)
Status:
Recruiting
Trial end date:
2022-12-13
Target enrollment:
Participant gender:
Summary
The principal goal of this study is to determine the efficacy of efinopegdutide in liver fat
reduction in participants with NAFLD. The primary hypotheses are that efinopegdutide is
superior to semaglutide, or that efinopegdutide is superior to semaglutide by at least 10%
with respect to mean relative reduction from baseline in liver fat content (LFC) after 24
weeks.